Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Martin Wisher
Advertisement
Martin Wisher, PHD, is senior director, global head of regulatory affairs for BioReliance at MilliporeSigma.
Articles by Martin Wisher
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsSeptember 1st 2018
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
3
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
4
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
5